DE10234192B4 - Verwendung von Erythropoetin - Google Patents
Verwendung von Erythropoetin Download PDFInfo
- Publication number
- DE10234192B4 DE10234192B4 DE10234192A DE10234192A DE10234192B4 DE 10234192 B4 DE10234192 B4 DE 10234192B4 DE 10234192 A DE10234192 A DE 10234192A DE 10234192 A DE10234192 A DE 10234192A DE 10234192 B4 DE10234192 B4 DE 10234192B4
- Authority
- DE
- Germany
- Prior art keywords
- erythropoietin
- use according
- cells
- endothelial
- epo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims description 94
- 102000003951 Erythropoietin Human genes 0.000 title claims description 80
- 108090000394 Erythropoietin Proteins 0.000 title claims description 80
- 229940105423 erythropoietin Drugs 0.000 title claims description 79
- 230000003511 endothelial effect Effects 0.000 claims abstract description 96
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 7
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims abstract description 6
- 102100035194 Placenta growth factor Human genes 0.000 claims abstract description 6
- 230000004048 modification Effects 0.000 claims abstract description 3
- 238000012986 modification Methods 0.000 claims abstract description 3
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims abstract 2
- 210000000130 stem cell Anatomy 0.000 claims description 94
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 5
- 102000044890 human EPO Human genes 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 2
- 229950009116 mevastatin Drugs 0.000 claims description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 abstract description 42
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- 230000004069 differentiation Effects 0.000 abstract description 14
- 230000002491 angiogenic effect Effects 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 230000005012 migration Effects 0.000 abstract description 11
- 238000013508 migration Methods 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 11
- 230000002792 vascular Effects 0.000 abstract description 11
- 230000004862 vasculogenesis Effects 0.000 abstract description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract description 8
- 239000002243 precursor Substances 0.000 abstract description 8
- 230000000982 vasogenic effect Effects 0.000 abstract description 8
- 210000000056 organ Anatomy 0.000 abstract description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract description 6
- 230000004936 stimulating effect Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- WGUYYUOFQYVTLR-BLPRJPCASA-N [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO Chemical compound [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO WGUYYUOFQYVTLR-BLPRJPCASA-N 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 210000003709 heart valve Anatomy 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 230000004064 dysfunction Effects 0.000 description 18
- 102100031939 Erythropoietin Human genes 0.000 description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 14
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 13
- 206010029113 Neovascularisation Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 210000003038 endothelium Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 208000020832 chronic kidney disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- 102100022987 Angiogenin Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 210000001956 EPC Anatomy 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 241000219871 Ulex Species 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000004670 arteriolosclerosis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010046015 ferritin receptor Proteins 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (58)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| US10/522,426 US7745387B2 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| HR20050065A HRP20050065A2 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| DK03766302T DK1526867T3 (da) | 2002-07-26 | 2003-07-25 | Erythropoietin i subpolycytæmiske doser |
| EA200700196A EA013966B1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина для лечения сахарного диабета |
| DE50307140T DE50307140D1 (en) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen |
| JP2004525322A JP4727988B2 (ja) | 2002-07-26 | 2003-07-25 | エリスロポエチンの使用 |
| DK07001689.4T DK1779862T3 (da) | 2002-07-26 | 2003-07-25 | Erythropoietin i subpolycytæmiske doser til behandling af diabetes |
| MXPA05001120A MXPA05001120A (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina para la estimulacion de celulas precursoras endoteliales. |
| SG2007003890A SG177004A1 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| SI200330881T SI1526867T1 (sl) | 2002-07-26 | 2003-07-25 | Eritropoetin v sub-policitemiäśnih dozah |
| CNA038221160A CN1681526A (zh) | 2002-07-26 | 2003-07-25 | 促红细胞生成素的应用 |
| PT03766302T PT1526867E (pt) | 2002-07-26 | 2003-07-25 | Eritropoietina em doses sub-policitémicas |
| EP03766302A EP1526867B1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen |
| KR1020057001341A KR20050026513A (ko) | 2002-07-26 | 2003-07-25 | 에리스로포이에틴의 용도 |
| EP10000381A EP2191838A1 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur Stimulation endothelialer Vorläuferzellen |
| HR20100187A HRP20100187A2 (hr) | 2002-07-26 | 2003-07-25 | Uporaba eritropoetina |
| PL395151A PL395151A1 (pl) | 2002-07-26 | 2003-07-25 | Zastosowanie erytropoetyny |
| DE50312729T DE50312729D1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes |
| EA200801236A EA200801236A1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина |
| SI200331837T SI1779862T1 (sl) | 2002-07-26 | 2003-07-25 | Eritropoietin v subpolicitemskih odmerkih za zdravljenje diabetesa |
| AT03766302T ATE360436T1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen |
| EA200500281A EA009463B1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина |
| CN200710127913XA CN101099731B (zh) | 2002-07-26 | 2003-07-25 | 促红细胞生成素的应用 |
| ES07001689T ES2345673T3 (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina en dosis subpolicitemicas para el tratamiento de la diabetes. |
| UAA200801307A UA94913C2 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина для лечения сахарного диабета |
| BR0312981-0A BR0312981A (pt) | 2002-07-26 | 2003-07-25 | Uso da eritropoetina |
| HR20070189A HRP20070189A2 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| ES03766302T ES2285195T3 (es) | 2002-07-26 | 2003-07-25 | Eritropoyetina en dosis subpolicitemicas. |
| CA2710100A CA2710100A1 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| CN2007101279144A CN101099860B (zh) | 2002-07-26 | 2003-07-25 | 促红细胞生成素的应用 |
| CA002493598A CA2493598A1 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin_to treat renal failure |
| PT07001689T PT1779862E (pt) | 2002-07-26 | 2003-07-25 | Eritropoietina em doses sub-policitémicas para o tratamento de diabetes |
| EP07001689A EP1779862B1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes |
| PCT/EP2003/008229 WO2004012759A2 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur stimulation endothelialer voläuferzellen |
| PL03374874A PL374874A1 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| AU2003255290A AU2003255290B2 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| UAA200501760A UA85997C2 (en) | 2002-07-26 | 2003-07-25 | Use of erythropoietin |
| KR1020107011097A KR20100077033A (ko) | 2002-07-26 | 2003-07-25 | 에리스로포이에틴의 용도 |
| HK05109837.3A HK1081841B (zh) | 2002-07-26 | 2003-07-25 | 亚红细胞增多剂量中的促红细胞生成素 |
| AT07001689T ATE468132T1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes |
| IS7633A IS2671B (is) | 2002-07-26 | 2005-01-06 | Rauðkornavaki í undirblóðríkisskömmtum |
| IL16640105A IL166401A0 (en) | 2002-07-26 | 2005-01-20 | Pharmaceutical compositions containing endothelialer |
| ZA200500726A ZA200500726B (en) | 2002-07-26 | 2005-01-25 | Use of erythropoietin |
| NO20051002A NO20051002L (no) | 2002-07-26 | 2005-02-24 | Anvendelse av erytropoietin |
| CY20071100871T CY1108052T1 (el) | 2002-07-26 | 2007-07-02 | Ερυθροποιητiνη σε υποπολυκυτταραιμικeς δoσεις |
| HK07111782.2A HK1108625B (en) | 2002-07-26 | 2007-10-31 | Erythropoietin in subpolycythemic doses for treating diabetes |
| AU2009200748A AU2009200748A1 (en) | 2002-07-26 | 2009-02-25 | Use of erythropoietin |
| IS8817A IS8817A (is) | 2002-07-26 | 2009-05-06 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
| IL204577A IL204577A (en) | 2002-07-26 | 2010-03-18 | Pharmaceutical compositions containing erythropoietin for the treatment of diabetes mellitus |
| US12/759,321 US20100247452A1 (en) | 2002-07-26 | 2010-04-13 | Use of erythropoietin |
| US12/759,299 US20100247451A1 (en) | 2002-07-26 | 2010-04-13 | Use of erythropoietin |
| US12/759,275 US20100247450A1 (en) | 2002-07-26 | 2010-04-13 | Use of erythropoietin |
| IS8909A IS8909A (is) | 2002-07-26 | 2010-07-02 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
| JP2010157094A JP2010280672A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157093A JP2010280671A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| JP2010157092A JP2010280670A (ja) | 2002-07-26 | 2010-07-09 | エリスロポエチンの使用 |
| CY20101100712T CY1110713T1 (el) | 2002-07-26 | 2010-07-29 | Ερυθροποιητινη σε υποπολυκυτταραιμικες δοσεις για τη θεραπεια του διαβητη |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| DE10262245 | 2002-07-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10234192A1 DE10234192A1 (de) | 2004-02-12 |
| DE10234192B4 true DE10234192B4 (de) | 2009-11-26 |
Family
ID=30128436
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10234192A Expired - Fee Related DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| DE50307140T Expired - Lifetime DE50307140D1 (en) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen |
| DE50312729T Expired - Lifetime DE50312729D1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50307140T Expired - Lifetime DE50307140D1 (en) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen |
| DE50312729T Expired - Lifetime DE50312729D1 (de) | 2002-07-26 | 2003-07-25 | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7745387B2 (enExample) |
| EP (3) | EP1779862B1 (enExample) |
| JP (4) | JP4727988B2 (enExample) |
| KR (2) | KR20050026513A (enExample) |
| CN (3) | CN101099860B (enExample) |
| AT (2) | ATE360436T1 (enExample) |
| AU (2) | AU2003255290B2 (enExample) |
| BR (1) | BR0312981A (enExample) |
| CA (2) | CA2493598A1 (enExample) |
| CY (2) | CY1108052T1 (enExample) |
| DE (3) | DE10234192B4 (enExample) |
| DK (2) | DK1526867T3 (enExample) |
| EA (3) | EA200801236A1 (enExample) |
| ES (2) | ES2345673T3 (enExample) |
| HR (3) | HRP20100187A2 (enExample) |
| IL (2) | IL166401A0 (enExample) |
| IS (3) | IS2671B (enExample) |
| MX (1) | MXPA05001120A (enExample) |
| NO (1) | NO20051002L (enExample) |
| PL (2) | PL374874A1 (enExample) |
| PT (2) | PT1779862E (enExample) |
| SG (1) | SG177004A1 (enExample) |
| SI (2) | SI1526867T1 (enExample) |
| UA (2) | UA94913C2 (enExample) |
| WO (1) | WO2004012759A2 (enExample) |
| ZA (1) | ZA200500726B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| PT1660115E (pt) * | 2003-07-29 | 2011-08-24 | Dompe Spa | ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE |
| ES2346226T3 (es) * | 2003-12-30 | 2010-10-13 | Augustinus Bader | Uso de la eritropoyetina para la regeneracion de tejido hepatico. |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| KR20070089996A (ko) | 2004-12-06 | 2007-09-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 세동맥의 구조 및 기능의 개선 방법 |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CN101460188B (zh) * | 2006-06-07 | 2013-09-04 | 国立大学法人德岛大学 | 使用促红细胞生成素的局部缺血疾病的治疗 |
| MX2009003441A (es) * | 2006-09-29 | 2009-10-16 | Centocor Ortho Biotech Inc | Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| JP5378795B2 (ja) * | 2006-10-20 | 2013-12-25 | 中外製薬株式会社 | 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物 |
| AU2007311946A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008086025A2 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| US20110123481A1 (en) * | 2007-08-16 | 2011-05-26 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| WO2009143268A2 (en) * | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR102170682B1 (ko) * | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| US9956265B2 (en) | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| US20160279297A1 (en) * | 2013-10-22 | 2016-09-29 | ConcieValve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| US11241505B2 (en) * | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019078344A1 (ja) * | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| TWI822728B (zh) | 2018-01-31 | 2023-11-21 | 加藤元一 | 含有il-6抑制劑的哮喘治療劑 |
| RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| AU2020259884A1 (en) | 2019-04-17 | 2021-10-07 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| CA3145425A1 (en) | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP4674480A3 (en) | 2020-10-02 | 2026-04-08 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| CN119080909A (zh) * | 2024-08-29 | 2024-12-06 | 深圳赛保尔生物药业有限公司 | 负载peg-epo及间充质干细胞的组合物、药物及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| WO1995019793A1 (en) * | 1994-01-21 | 1995-07-27 | The United States Of America, Represented By The Secretary Of The Navy | Hematopoietic cell expansion and transplantation methods |
| WO1998010650A1 (en) * | 1996-09-11 | 1998-03-19 | East Carolina University | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| WO2000061164A1 (en) * | 1999-04-13 | 2000-10-19 | Kenneth S. Warren Laboratories | Modulation of excitable tissue function by peripherally administered erythropoietin |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| EP0246322B1 (en) | 1985-11-27 | 1992-08-26 | Genetics Institute, Inc. | Treatment of aids-type disease |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| AU4072189A (en) * | 1988-02-24 | 1989-09-22 | American National Red Cross, The | Device for site directed neovascularization and method for same |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| DK0575555T3 (da) * | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| KR960701650A (ko) | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| EP0784480B1 (en) | 1994-11-03 | 2003-10-15 | Boehringer Mannheim Gmbh | Use of erythropoietin in the treatment of rheumatoid arthritis |
| US5837675A (en) * | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
| US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| DE60131393D1 (de) | 2000-05-02 | 2007-12-27 | Action Pharma As | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| JP2005503127A (ja) * | 2001-04-04 | 2005-02-03 | ジェンオディセ | エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| CA2468499A1 (en) * | 2001-11-28 | 2003-06-05 | Ortho-Mcneil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
| US7335490B2 (en) | 2002-01-09 | 2008-02-26 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
| US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
-
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| WO1995019793A1 (en) * | 1994-01-21 | 1995-07-27 | The United States Of America, Represented By The Secretary Of The Navy | Hematopoietic cell expansion and transplantation methods |
| WO1998010650A1 (en) * | 1996-09-11 | 1998-03-19 | East Carolina University | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| WO2000061164A1 (en) * | 1999-04-13 | 2000-10-19 | Kenneth S. Warren Laboratories | Modulation of excitable tissue function by peripherally administered erythropoietin |
Non-Patent Citations (8)
| Title |
|---|
| Abstract zu Alvarez Aroyo MV(u.a.): Role of vascular endothelial growth factor on erythropoietin- related endothelial cell proliferation. In: J. Am. Soc. Nephrol. , 1998, Vol. 9, No. 11, S. 1998-2004 * |
| Asahara, T. (u.a.): VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derives endothelial progenitor cells. In: EMBO Journal. 1999m Vol. 18, Vol. 14, S. 3964-3972 * |
| BIOSIS-Abstract 2002:261552 zu Arcasoy, M.O. (u.a. ): Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing. In: Blood, 2001, Vol. 98, NO. 11, S. 822a-832a * |
| Internet recherche am 15.04.2003:http://www.ncbi. nlm.nih.gov/entrez, Buemi, M., Aloisi, C., Cavallaro, E., [u.a.]: Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. 2002 Mar-Apr. In: J. Nephrol., Vol. 15, S. 97-103, PubMed-Abstr.: 12018644 * |
| Internet recherche am 15.04.2003:http://www.ncbi. nlm.nih.gov/entrez, Buemi, M., Aloisi, C., Cavallaro, E., [u.a.]: Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. 2002 Mar-Apr. In: J. Nephrol., Vol. 15, S. 97-103, PubMed-Abstr.: 12018644 Llevadot, J. (u.a.): HMG-CoA reductase inhibitor nobilizes bone marrow-derived progenitor cells. In: J. Clin. Invest., 2002, Vol. 108, S. 399-405 BIOSIS-Abstract 2002:261552 zu Arcasoy, M.O. (u.a. ): Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing. In: Blood, 2001, Vol. 98, NO. 11, S. 822a-832a Medline-Abstracts zu Cases A.: Recombinated human erythropoietin treatment in chronic renal failure: effects on hemostasis and vasculature. In: Drugs Today, 2000, Vol. 36, No. 8, S. 541-556 Abstract zu Alvarez Aroyo MV(u.a.): Role of vascular endothelial growth factor on erythropoietin- related endothelial cell proliferation. In: J. Am. Soc. Nephrol. , 1998, Vol. 9, No. 11, S. 1998-2004 |
| Jaquet, K. (u.a.): Erythropoitin and VEGF Exhibit Equal Angiogenic Potential. In: Microvascular Research, 2002, Vol. 64, S. 326-333 * |
| Llevadot, J. (u.a.): HMG-CoA reductase inhibitor nobilizes bone marrow-derived progenitor cells. In: J. Clin. Invest., 2002, Vol. 108, S. 399-405 * |
| Medline-Abstracts zu Cases A.: Recombinated human erythropoietin treatment in chronic renal failure: effects on hemostasis and vasculature. In: Drugs Today, 2000, Vol. 36, No. 8, S. 541-556 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1779862B1 (de) | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes | |
| Kawamoto et al. | Nerve growth factor and wound healing | |
| DE102004004509B4 (de) | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden | |
| DE69736712T2 (de) | Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden | |
| DE69228700T2 (de) | Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände | |
| DE69535593T2 (de) | Verwendung von hgf zur herstellung eines arzneimittels zur behandlung von lungenfibrose | |
| DE4132005A1 (de) | Kombination enthaltend wachstumsfaktoren und polyelektrolyte | |
| EP2679239A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit | |
| DE69835016T2 (de) | Verwendung von midkin oder von anti-midkin antikörper | |
| US7803522B2 (en) | Elastin producing fibroblast formulations and methods of using the same | |
| DE60021360T2 (de) | Vegf angiogenische wachstumsfaktoren zur behandlung von peripherer neuropathie | |
| DE69232596T2 (de) | Inhibitor von nebenwirkungen zur krebstherapy | |
| DE60128399T2 (de) | Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen | |
| DE69836830T2 (de) | Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten | |
| EP2572724A1 (de) | Behandlung von Fibrosen und Lebererkrankungen | |
| DE19826628C1 (de) | Intranasale Verwendung von Insulin bei Hirnleistungsstörungen | |
| EP2195014A2 (de) | Verwendung von g-csf für die behandlung von schlaganfall | |
| DE19837230A1 (de) | Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs | |
| NZ553426A (en) | Use of erythropoietin for treating diabetes mellitus | |
| DE19604858A1 (de) | Verwendung von Interferon-gamma (IFN-gamma) zur Herstellung einer pharmazeutischen Präparation zur Prophylaxe und/oder Behandlung von Erkrankungen, die mit einer Überexpression von Amyloid-Vorläuferprotein einhergehen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: EPOPLUS GMBH CO.KG, 30625 HANNOVER, DE |
|
| 8172 | Supplementary division/partition in: |
Ref document number: 10262245 Country of ref document: DE Kind code of ref document: P |
|
| Q171 | Divided out to: |
Ref document number: 10262245 Country of ref document: DE Kind code of ref document: P |
|
| AH | Division in |
Ref document number: 10262245 Country of ref document: DE Kind code of ref document: P |
|
| 8364 | No opposition during term of opposition | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20120201 |